false 0001563880 0001563880 2022-06-23 2022-06-23

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 23, 2022

 

Trevi Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

001-38886

 

45-0834299

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

195 Church Street, 14th Floor

New Haven, Connecticut

 

06510

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (203) 304-2499

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.001 par value per share

 

TRVI

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

At the 2022 annual meeting of stockholders of Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), held on June 23, 2022, the Company’s stockholders voted on the following proposals:

1. The following nominees were elected to the Board of Directors of the Company as Class III directors for terms expiring at the 2025 annual meeting of stockholders.

 

 

 

For

 

 

Withheld

 

 

Broker Non-Votes

 

Jennifer Good

 

 

21,768,228

 

 

 

178,450

 

 

 

9,566,404

 

Anne VanLent

 

 

21,763,978

 

 

 

182,700

 

 

 

9,566,404

 

2. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021 was ratified.

 

For:

 

 

31,324,562

 

Against:

 

 

8,689

 

Abstain:

 

 

179,831

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TREVI THERAPEUTICS, INC.

 

 

 

Date: June 23, 2022

 

By:

/s/ Lisa Delfini

 

 

 

Name: Lisa Delfini

 

 

 

Title: Chief Financial Officer

 

Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Trevi Therapeutics Charts.
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Trevi Therapeutics Charts.